LAVA Therapeutics NVNASDAQ:LVTX
- LAST PRICE2.6400
- TODAY'S CHANGE (%)-0.1200 (-4.3478%)
- Bid / Lots2.6700/ 2
- Ask / Lots2.9500/ 1
- Open / Previous Close2.7700 / 2.7600
- Day Range
- 52 Week Range
- Volume47,187
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LVTX |
|---|---|---|
| 09:38 ET | 200 | 2.777 |
| 09:43 ET | 166 | 2.7632 |
| 09:48 ET | 100 | 2.76 |
| 09:59 ET | 100 | 2.71 |
| 10:15 ET | 300 | 2.7101 |
| 10:33 ET | 310 | 2.754 |
| 10:57 ET | 100 | 2.77 |
| 11:04 ET | 130 | 2.7678 |
| 11:33 ET | 290 | 2.7673 |
| 12:09 ET | 100 | 2.765 |
| 12:12 ET | 100 | 2.75 |
| 12:50 ET | 100 | 2.75 |
| 01:10 ET | 400 | 2.76 |
| 01:26 ET | 100 | 2.74 |
| 01:44 ET | 285 | 2.74 |
| 01:50 ET | 100 | 2.745 |
| 01:51 ET | 1514 | 2.745 |
| 02:06 ET | 595 | 2.73 |
| 02:13 ET | 100 | 2.725 |
| 02:18 ET | 1658 | 2.7109 |
| 02:22 ET | 18151 | 2.628 |
| 02:29 ET | 100 | 2.65 |
| 02:33 ET | 230 | 2.6692 |
| 02:40 ET | 300 | 2.7002 |
| 02:44 ET | 100 | 2.68 |
| 02:47 ET | 2061 | 2.695 |
| 02:49 ET | 400 | 2.655 |
| 03:05 ET | 100 | 2.67 |
| 03:09 ET | 3200 | 2.67 |
| 03:12 ET | 2050 | 2.68 |
| 03:20 ET | 200 | 2.65 |
| 03:32 ET | 386 | 2.65 |
| 03:34 ET | 300 | 2.6699 |
| 03:36 ET | 1700 | 2.67 |
| 03:52 ET | 100 | 2.665 |
| 03:54 ET | 200 | 2.68 |
| 03:56 ET | 100 | 2.69 |
| 03:57 ET | 1198 | 2.6575 |
| 03:59 ET | 3486 | 2.64 |
May 6, 2024
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference, from 4:05PM ET on Monday May 06, 2024 by Dow Jones
4:05PM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LAVA Therapeutics NV | 72.6M | -1.7x | --- |
Atara Biotherapeutics Inc | 72.7M | -0.3x | --- |
Kronos Bio Inc | 59.0M | -0.5x | --- |
Kezar Life Sciences Inc | 55.9M | -0.5x | --- |
Ikena Oncology Inc | 67.6M | -0.9x | --- |
Cue Biopharma Inc | 84.6M | -1.6x | --- |
Company Information
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact Information
- Headquarters
- Yalelaan 60UTRECHT, Netherlands 3584 CM
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Kapil Dhingra
- President, Chief Executive Officer, Management Director
- Stephen Hurly
- Chief Financial Officer
- Edward Smith
- Executive Vice President Head of Research and Development
- Paul Parren
- Chief Scientific Officer
- Hans Van Der Vliet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $69.4M |
|---|---|
Revenue (TTM) | $6.8M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.58 |
Book Value | $1.95 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 10.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -638.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
